Xintela AB (publ) (XINT.ST)
SEK 0.48
(43.07%)
SEK 0.48
(43.07%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -7.8 Million SEK | 6.4% |
| 2022 | -8.34 Million SEK | 16.07% |
| 2021 | -9.94 Million SEK | 56.21% |
| 2020 | -22.7 Million SEK | -5409.95% |
| 2019 | -412 Thousand SEK | 98.69% |
| 2018 | -31.39 Million SEK | -43.3% |
| 2017 | -21.91 Million SEK | -15.44% |
| 2016 | -18.97 Million SEK | -243.64% |
| 2015 | -5.52 Million SEK | -570.43% |
| 2014 | -823.79 Thousand SEK | 65.23% |
| 2013 | -2.36 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -445 Thousand SEK | 95.72% |
| 2024 Q1 | -10.4 Million SEK | -33.29% |
| 2023 Q4 | -7.8 Million SEK | 33.27% |
| 2023 Q2 | -697 Thousand SEK | 71.14% |
| 2023 Q3 | -11.7 Million SEK | -1579.05% |
| 2023 Q1 | -2.41 Million SEK | 71.05% |
| 2023 FY | -7.8 Million SEK | 6.4% |
| 2022 Q2 | -142 Thousand SEK | 93.84% |
| 2022 Q4 | -8.34 Million SEK | -850.23% |
| 2022 FY | -8.34 Million SEK | 16.07% |
| 2022 Q1 | -2.3 Million SEK | 76.82% |
| 2022 Q3 | -878 Thousand SEK | -518.31% |
| 2021 Q2 | -3.25 Million SEK | 74.39% |
| 2021 Q3 | -12.92 Million SEK | -297.51% |
| 2021 Q4 | -9.94 Million SEK | 23.08% |
| 2021 FY | -9.94 Million SEK | 56.21% |
| 2021 Q1 | -12.69 Million SEK | 44.08% |
| 2020 Q2 | 18.13 Million SEK | 5151.81% |
| 2020 FY | -22.7 Million SEK | -5409.95% |
| 2020 Q4 | -22.7 Million SEK | -966.28% |
| 2020 Q3 | -2.12 Million SEK | -111.74% |
| 2020 Q1 | -359 Thousand SEK | 12.86% |
| 2019 Q1 | -20.99 Million SEK | 33.13% |
| 2019 FY | -412 Thousand SEK | 98.69% |
| 2019 Q3 | -2.68 Million SEK | 76.3% |
| 2019 Q4 | -412 Thousand SEK | 84.66% |
| 2019 Q2 | -11.32 Million SEK | 46.04% |
| 2018 Q3 | -2.83 Million SEK | 65.38% |
| 2018 FY | -31.39 Million SEK | -43.3% |
| 2018 Q4 | -31.39 Million SEK | -1006.31% |
| 2018 Q1 | -12.53 Million SEK | 42.81% |
| 2018 Q2 | -8.19 Million SEK | 34.59% |
| 2017 Q4 | -21.91 Million SEK | -83.82% |
| 2017 FY | -21.91 Million SEK | -15.44% |
| 2017 Q1 | -22.47 Million SEK | -18.43% |
| 2017 Q2 | -17.69 Million SEK | 21.29% |
| 2017 Q3 | -11.91 Million SEK | 32.63% |
| 2016 FY | -18.97 Million SEK | -243.64% |
| 2016 Q4 | -18.97 Million SEK | 17.58% |
| 2016 Q3 | -23.02 Million SEK | 13.31% |
| 2016 Q2 | -26.56 Million SEK | -580.93% |
| 2016 Q1 | 5.52 Million SEK | 200.0% |
| 2015 FY | -5.52 Million SEK | -570.43% |
| 2015 Q4 | -5.52 Million SEK | 0.0% |
| 2015 Q1 | 824 Thousand SEK | 0.0% |
| 2014 FY | -823.79 Thousand SEK | 65.23% |
| 2013 FY | -2.36 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Asarina Pharma AB (publ) | -2.16 Million SEK | -261.36% |
| BioArctic AB (publ) | -606.58 Million SEK | 98.713% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | 59.029% |
| CombiGene AB (publ) | -101.44 Million SEK | 92.302% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 90.487% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 73.423% |
| OncoZenge AB (publ) | -12.62 Million SEK | 38.156% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 84.389% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 244.611% |
| Mendus AB (publ) | -96.29 Million SEK | 91.89% |
| LIDDS AB (publ) | -13.51 Million SEK | 42.207% |
| Lipum AB (publ) | -8.46 Million SEK | 7.75% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 114.672% |
| Simris Alg AB (publ) | 85.07 Million SEK | 109.179% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 82.73% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | 40.971% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 104.702% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 93.97% |
| Ziccum AB (publ) | -2.13 Million SEK | -265.419% |
| AcouSort AB (publ) | -23.98 Million SEK | 67.444% |
| Active Biotech AB (publ) | -33.2 Million SEK | 76.479% |
| Alzinova AB (publ) | -21.22 Million SEK | 63.21% |
| Amniotics AB (publ) | -5.63 Million SEK | -38.654% |
| Camurus AB (publ) | -1.16 Billion SEK | 99.33% |
| Cantargia AB (publ) | -139.74 Million SEK | 94.412% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -746.046% |
| Genovis AB (publ.) | -43.94 Million SEK | 82.228% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 90.675% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 94.347% |
| Intervacc AB (publ) | -88.16 Million SEK | 91.142% |
| Kancera AB (publ) | -45.69 Million SEK | 82.909% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 90.5% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 75.541% |
| NextCell Pharma AB | -46.79 Million SEK | 83.311% |
| Saniona AB (publ) | 40.44 Million SEK | 119.307% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 97.659% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 84.361% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 138.074% |
| Corline Biomedical AB | -17.01 Million SEK | 54.097% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 90.675% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 80.171% |
| Aptahem AB (publ) | 2.9 Million SEK | 368.476% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 97.627% |
| Fluicell AB (publ) | -2.76 Million SEK | -182.628% |
| Biovica International AB (publ) | -58.73 Million SEK | 86.705% |
| Abliva AB (publ) | -57.24 Million SEK | 86.357% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 95.989% |
| 2cureX AB (publ) | -13.4 Million SEK | 41.737% |
| I-Tech AB | -83.26 Million SEK | 90.621% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 105.797% |
| Cyxone AB (publ) | -16.67 Million SEK | 53.155% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 86.027% |
| Biosergen AB | -1.88 Million SEK | -314.711% |
| Nanologica AB (publ) | -9.38 Million SEK | 16.819% |
| SynAct Pharma AB | -61.75 Million SEK | 87.355% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 63.535% |
| BioInvent International AB (publ) | -236.3 Million SEK | 96.695% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 88.331% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -50.726% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | 62.444% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -162.752% |